CLINICAL TRIALS PROFILE FOR MD-GASTROVIEW

All Clinical Trials for MD-GASTROVIEW

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00478556 ↗	Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT	Completed	GE Healthcare	Phase 4	2007-08-01	Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00478556 ↗	Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT	Completed	University of Alabama at Birmingham	Phase 4	2007-08-01	Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT01790139 ↗	Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles	Completed	GE Healthcare	N/A	2013-02-01	To determine whether colonic bubbles associated with CT colonography performed with iohexol for fecal/fluid tagging could be reduced by adding simethicone to the standard cathartic preparation.
NCT01790139 ↗	Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles	Completed	Asan Medical Center	N/A	2013-02-01	To determine whether colonic bubbles associated with CT colonography performed with iohexol for fecal/fluid tagging could be reduced by adding simethicone to the standard cathartic preparation.
NCT02928458 ↗	Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol	Withdrawn	The Guthrie Clinic	N/A	2015-09-01	This research study is for patients with adhesive small bowel obstruction (ASBO). ASBO is a condition in which the small intestine gets blocked due to scars called adhesions. To see the blockage, a contrast agent is given and an x-ray is taken of the belly (abdomen). MD Gastroview and omnipaque are two contrast agents that may be given as part of your normal care for ASBO. This study hopes to see if one is better than the other.

Clinical Trial Conditions for MD-GASTROVIEW

Condition Name

Condition Name for MD-GASTROVIEW
Intervention	Trials
Intestinal Obstruction	1
Colorectal Neoplasms	1
Healthy	1

Condition MeSH

Condition MeSH for MD-GASTROVIEW
Intervention	Trials
Intestinal Obstruction	1
Colorectal Neoplasms	1

Clinical Trial Locations for MD-GASTROVIEW

Trials by Country

Trials by Country for MD-GASTROVIEW
Location	Trials
United States	2
Korea, Republic of	1

Trials by US State

Trials by US State for MD-GASTROVIEW
Location	Trials
Pennsylvania	1
Alabama	1

Clinical Trial Progress for MD-GASTROVIEW

Clinical Trial Phase

Clinical Trial Phase for MD-GASTROVIEW
Clinical Trial Phase	Trials
Phase 4	1
N/A	2

Clinical Trial Status

Clinical Trial Status for MD-GASTROVIEW
Clinical Trial Phase	Trials
Completed	2
Withdrawn	1

Clinical Trial Sponsors for MD-GASTROVIEW

Sponsor Name

Sponsor Name for MD-GASTROVIEW
Sponsor	Trials
GE Healthcare	2
University of Alabama at Birmingham	1
Asan Medical Center	1

Sponsor Type

Sponsor Type for MD-GASTROVIEW
Sponsor	Trials
Other	3
Industry	2

Last updated: June 8, 2026

MD-GASTROVIEW Clinical Trials Update, Market Analysis, and Revenue Projection: Latest Enrollment, Key Signals, and Likely Launch Scenarios

What is MD-GASTROVIEW and what is in its clinical pipeline?

MD-GASTROVIEW is not identifiable from the provided input as a specific, FDA-submitted, or publicly documented drug product. No reliable mapping to an active ingredient, developer, IND/NCT record, trial phase, indication, formulation, or dosing regimen can be produced from the request alone.

What clinical trials are ongoing for MD-GASTROVIEW (NCT status, phase, sites, enrollment)?

No verifiable clinical trial identifiers (NCT numbers), phase designations, enrollment targets, recruitment status, or principal endpoints are provided, and no specific public trial record can be confirmed for “MD-GASTROVIEW” from the available information in the prompt.

When will MD-GASTROVIEW read out primary endpoints and what trial milestones matter for approval?

No protocol details are provided. Without a confirmed IND and trial record, primary endpoint timing, top-line readout windows, and pivotal-study completion dates cannot be stated accurately.

What regulatory pathway is MD-GASTROVIEW targeting and what is its FDA status (IND, NDA, BLA, Fast Track)?

No FDA submission status, reference product, proposed indication, or regulatory designations are supplied. Without a verified product identity and sponsor mapping, an FDA pathway assessment cannot be generated.

What patents protect MD-GASTROVIEW and how do exclusivity timelines affect generic or biosimilar entry risk?

No patent estate, Orange Book listings, or exclusivity claims are provided. Without confirmation of the active ingredient, dosage form, and jurisdictional filing history, expiration and Paragraph IV risk can’t be calculated.

What is the market size for MD-GASTROVIEW’s target indication and who are the competitors?

No indication, geography, patient population definition, pricing basis, or comparator set is provided. Market projection requires at least indication, route of administration, efficacy positioning, and payer dynamics, none of which are present.

How strong is MD-GASTROVIEW’s clinical differentiation versus standard of care?

No efficacy or safety signals are provided (response rates, symptom score changes, endoscopic outcomes, relapse rates, time-to-event endpoints, adverse event profile). Differentiation cannot be quantified without trial results or protocol endpoints.

What pricing and reimbursement scenario is likely for MD-GASTROVIEW in the US and EU?

No pricing assumptions, payer constraints, or health technology assessment context are provided. A credible forecast depends on drug class comparables and negotiated outcomes, which cannot be derived from “MD-GASTROVIEW” alone.

What revenue projection model applies to MD-GASTROVIEW and what launch uptake assumptions are required?

A revenue projection requires verified launch timing, label scope, treatment course length, eligible patient estimate, uptake ramp, penetration over comparators, and persistence. None are available in the prompt and no validated product mapping is possible.

What generic entry risks exist for MD-GASTROVIEW and when could competitors launch?

No Orange Book data, patent expiration dates, or generic settlement history is provided. Without confirmed IP and exclusivity records, launch risk timing is not computable.

How does MD-GASTROVIEW compare with closest-in-class drugs in sales terms and clinical evidence?

No comparator list or sales benchmarks are provided. A comparative evidence map needs trial head-to-heads or matched endpoints plus competitor market share or unit utilization.

Key Takeaways

• MD-GASTROVIEW cannot be reliably identified to a specific active ingredient, sponsor, regulatory dossier, clinical-trial record, patent estate, or competitive set based on the input provided.
• Clinical-trials update, regulatory pathway status, exclusivity and patent timing, and market sizing and revenue projections cannot be produced without confirmed product identity tied to public records.

FAQs

1. What does “MD-GASTROVIEW” correspond to in regulatory submissions (IND/NDA/BLA)?
2. Which NCT trials are associated with MD-GASTROVIEW and what are their primary endpoints?
3. Does MD-GASTROVIEW have Fast Track, Breakthrough Therapy, or Orphan Drug status?
4. What does the Orange Book list for MD-GASTROVIEW, including patents and exclusivity expirations?
5. What competitors treat the same GI indication and what evidence benchmarks define differentiation?

References

No sources cited.